Vineet Laboratories Ltd

Vineet Laboratories Ltd

₹ 58.5 -0.56%
04 Jul - close price
About

Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs

Key Points

Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.

  • Market Cap 54.0 Cr.
  • Current Price 58.5
  • High / Low 89.0 / 46.1
  • Stock P/E 52.4
  • Book Value 37.7
  • Dividend Yield 0.00 %
  • ROCE 7.15 %
  • ROE 3.01 %
  • Face Value 10.0

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Promoter holding is low: 37.5%
  • Tax rate seems low
  • Company has a low return on equity of 9.14% over last 3 years.
  • Working capital days have increased from 73.4 days to 126 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
243.48 57.67 39.55 38.36 55.59 48.82 39.51 66.76 57.20 37.52 43.37 32.65 37.05
235.33 54.94 37.74 35.72 49.52 44.90 43.52 64.81 51.39 37.26 39.20 33.29 33.63
Operating Profit 8.15 2.73 1.81 2.64 6.07 3.92 -4.01 1.95 5.81 0.26 4.17 -0.64 3.42
OPM % 3.35% 4.73% 4.58% 6.88% 10.92% 8.03% -10.15% 2.92% 10.16% 0.69% 9.61% -1.96% 9.23%
0.39 0.03 0.16 -0.01 0.11 0.08 0.00 0.00 0.03 0.03 0.01 0.01 0.41
Interest 2.67 0.54 0.49 0.35 0.79 1.37 0.61 1.03 0.37 0.96 1.02 1.08 1.72
Depreciation 1.81 0.49 0.50 0.50 0.52 0.54 0.70 0.51 0.62 0.61 0.61 0.63 0.67
Profit before tax 4.06 1.73 0.98 1.78 4.87 2.09 -5.32 0.41 4.85 -1.28 2.55 -2.34 1.44
Tax % 56.16% 26.01% 25.51% 23.60% 32.44% 51.67% 11.84% -239.02% 26.80% 2.34% 4.71% 11.11% -34.03%
1.78 1.28 0.72 1.36 3.28 1.01 -4.70 1.39 3.55 -1.25 2.42 -2.07 1.92
EPS in Rs 1.93 1.39 0.78 1.48 3.56 1.10 -5.10 1.51 3.85 -1.36 2.63 -2.25 2.08
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
0 243 191 212 151
0 235 178 205 143
Operating Profit -0 8 13 8 7
OPM % 3% 7% 4% 5%
0 0 0 0 0
Interest 0 3 2 3 5
Depreciation 0 2 2 2 3
Profit before tax -0 4 9 2 0
Tax % 0% 56% 29% 38% -183%
-0 2 7 1 1
EPS in Rs -0.24 1.93 7.20 1.36 1.12
Dividend Payout % 0% 0% 14% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: -15%
TTM: -29%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: -17%
TTM: -18%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: -16%
1 Year: 9%
Return on Equity
10 Years: %
5 Years: %
3 Years: 9%
Last Year: 3%

Balance Sheet

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 0 9 9 9 9
Reserves -0 17 24 24 26
0 12 27 31 44
0 70 74 51 38
Total Liabilities 0 109 133 116 117
0 20 21 27 27
CWIP 0 0 0 0 0
Investments 0 0 0 0 0
0 89 112 89 90
Total Assets 0 109 133 116 117

Cash Flows

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
0 27 8 -10 -11
0 -8 -4 -7 0
0 19 12 0 11
Net Cash Flow 0 38 16 -16 -0

Ratios

Figures in Rs. Crores

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 64 69 60 77
Inventory Days 73 109 98 158
Days Payable 114 161 74 103
Cash Conversion Cycle 23 17 84 131
Working Capital Days 28 28 66 126
ROCE % 34% 23% 9%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
35.96% 35.96% 35.96% 35.96% 35.96% 35.96% 35.96% 38.66% 38.66% 38.66% 37.55% 37.50%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.24% 0.00%
64.04% 64.04% 64.04% 64.04% 64.04% 64.04% 64.03% 61.35% 61.34% 61.34% 62.20% 62.50%
No. of Shareholders 7,3999,2169,1599,1649,5789,4369,5279,8219,3069,4699,5149,638

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents